Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AtriCure (ATRC) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for AtriCure (ATRC) over the last 16 years, with Q3 2025 value amounting to $9.1 million.

  • AtriCure's Change in Accured Expenses rose 1694.44% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year increase of 27220.43%. This contributed to the annual value of $1.2 million for FY2024, which is 8962.98% down from last year.
  • Latest data reveals that AtriCure reported Change in Accured Expenses of $9.1 million as of Q3 2025, which was up 1694.44% from $6.7 million recorded in Q2 2025.
  • In the past 5 years, AtriCure's Change in Accured Expenses ranged from a high of $9.1 million in Q3 2025 and a low of -$14.9 million during Q1 2024
  • Over the past 5 years, AtriCure's median Change in Accured Expenses value was $2.7 million (recorded in 2021), while the average stood at $1.1 million.
  • As far as peak fluctuations go, AtriCure's Change in Accured Expenses surged by 102229.73% in 2021, and later plummeted by 69483.05% in 2022.
  • Over the past 5 years, AtriCure's Change in Accured Expenses (Quarter) stood at $4.3 million in 2021, then plummeted by 61.72% to $1.6 million in 2022, then soared by 341.95% to $7.2 million in 2023, then decreased by 17.76% to $6.0 million in 2024, then skyrocketed by 53.06% to $9.1 million in 2025.
  • Its Change in Accured Expenses stands at $9.1 million for Q3 2025, versus $6.7 million for Q2 2025 and -$12.6 million for Q1 2025.